January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Robert F. Kennedy Jr’s message of eliminating toxins and investigating public health agencies has resonated among a key group ...

United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

OpenAI has made headlines on more than one occasion over the last few months. Firstly, it was due to the sudden emergence of ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

MicroStrategy, the business intelligence firm and Bitcoin treasury company co-founded by Michael Saylor has rebranded to ...

Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...

MicroStrategy Inc. (NASDAQ:MSTR) has officially rebranded as Strategy, reflecting its sharpened focus on Bitcoin ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...

In his confirmation hearing, Robert F. Kennedy Jr told Bernie Sanders that he opposes health care as a human right. His ...